22 related articles for article (PubMed ID: 6665015)
1. Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice.
Nordquist RE; Savignac H; Pauly-Evers M; Walker G; Knoflach F; Borroni E; Glaentzlin P; Bohrmann B; Messer J; Ozmen L; Albientz A; Spooren W
Behav Pharmacol; 2008 Sep; 19(5-6):518-29. PubMed ID: 18690106
[TBL] [Abstract][Full Text] [Related]
2. Differences in behavioural effects of amphetamine and dopamine-related gene expression in wild-type and homozygous CCK2 receptor deficient mice.
Rünkorg K; Värv S; Matsui T; Kõks S; Vasar E
Neurosci Lett; 2006 Oct; 406(1-2):17-22. PubMed ID: 16916582
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin2 receptor-deficient mice display altered function of brain dopaminergic system.
Kõks S; Volke V; Veraksits A; Rünkorg K; Sillat T; Abramov U; Bourin M; Huotari M; Männistö PT; Matsui T; Vasar E
Psychopharmacology (Berl); 2001 Nov; 158(2):198-204. PubMed ID: 11702094
[TBL] [Abstract][Full Text] [Related]
4. Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice.
Ralph RJ; Paulus MP; Geyer MA
J Pharmacol Exp Ther; 2001 Jul; 298(1):148-55. PubMed ID: 11408536
[TBL] [Abstract][Full Text] [Related]
5. Locomotor activity induced by noncompetitive NMDA receptor antagonists versus dopamine transporter inhibitors: opposite strain differences in inbred long-sleep and short-sleep mice.
Hanania T; Zahniser NR
Alcohol Clin Exp Res; 2002 Apr; 26(4):431-40. PubMed ID: 11981117
[TBL] [Abstract][Full Text] [Related]
6. Genetic aspects of dopamine receptor binding in the mouse and rat brain: an overview.
Vadasz C; Laszlovszky I; De Simone PA; Fleischer A
J Neurochem; 1992 Sep; 59(3):793-808. PubMed ID: 1494909
[No Abstract] [Full Text] [Related]
7. [Use of inbred animals in microbiological research].
Baltrashevich AK
Vestn Akad Med Nauk SSSR; 1983; (9):63-8. PubMed ID: 6356681
[No Abstract] [Full Text] [Related]
8. Pharmacological and biochemical aspects of hyperkinetic disorders.
Leonard BE
Neuropharmacology; 1979 Dec; 18(12):923-9. PubMed ID: 43483
[No Abstract] [Full Text] [Related]
9. Genetic differences in brain dopamine receptors and amphetamine response: possible model for hyperkinetic children.
Helmeste DM; Seeman P
Prog Clin Biol Res; 1983; 135():401-3. PubMed ID: 6665015
[No Abstract] [Full Text] [Related]
10. The hyperkinetic child syndrome and brain monoamines: pharmacology and therapeutic implications.
Margolin DI
J Clin Psychiatry; 1978 Feb; 39(2):120-3, 7-30. PubMed ID: 344302
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
